Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036244 · ClinicalTrials.gov registry record · Phase 3
Synthetic Human Secretin in Children With Autism
A Phase 3 study, sponsored by Repligen Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00036244: Completed Phase 3 study, sponsored by Repligen Corporation.
NCT00036244 is a Phase 3 study that has completed, run by Repligen Corporation. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00036244, a Phase 3 study, has completed, sponsored by Repligen Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.
Interventions
- DRUG RG1068 (Synthetic Human Secretin)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-04 |
| Est. Completion | 2004-01 |
| Phase | Phase 3 |
What the finished NCT00036244 record still lists
NCT00036244 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which RG1068 (Synthetic Human Secretin) is the first listed.
NCT00036244 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00036244 about?
NCT00036244 is a clinical study titled "Synthetic Human Secretin in Children With Autism". The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.
What is the current status of trial NCT00036244?
This trial is currently completed. It is a Phase 3 study. The study started on 2002-04. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00036244?
The interventions under investigation include: RG1068 (Synthetic Human Secretin) (DRUG).
Who is sponsoring clinical trial NCT00036244?
This trial is sponsored by Repligen Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia